Overview

This trial is active, not recruiting.

Condition pancreatic cancer
Treatments veliparib, gemcitabine, intensity modulated radiation therapy
Phase phase 1
Target PARP
Sponsor Cedars-Sinai Medical Center
Collaborator AbbVie
Start date July 2013
End date July 2017
Trial size 34 participants
Trial identifier NCT01908478, IIS-ABT888-0002

Summary

This is a Phase I Study of veliparib (ABT-888) in combination with Gemcitabine and Intensity Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic Cancer.

Primary Objectives:

- Determine the maximum tolerable dose of veliparib in combination with gemcitabine and intensity modulated radiation therapy in patients with locally advanced pancreatic cancer.

- Determine the safety and toxicity of the combination of veliparib with gemcitabine and radiation therapy in patients with locally advanced pancreatic cancer

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
veliparib ABT-888
gemcitabine Gemzar
intensity modulated radiation therapy

Primary Outcomes

Measure
Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
time frame: Days 1-70

Secondary Outcomes

Measure
Assessment of objective response rates measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
time frame: From baseline to Week 26
Evaluation of pre-treatment biopsy specimens for levels of various DNA repair proteins
time frame: Baseline only
Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells
time frame: Baseline, Weekly for 6 weeks, and at Weeks 10, 18, and 26

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with histopathological or cytological diagnosis of adenocarcinoma of the pancreas, as well as those with high clinical suspicion of adenocarcinoma, which is deemed locally advanced unresectable or borderline resectable as determined by a pancreatic cancer surgeon and/or following evaluation by a GI oncology tumor board. - Age 18 years or older Exclusion Criteria: - Patients who have had prior anti-cancer treatment for their disease - Patients who are currently receiving any other investigational agents - Metastatic disease - History of allergic reactions attributed to compounds of similar chemical or biologic composition to PARP [Poly (ADP-ribosome) polymerase] inhibitors or gemcitabine - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Additional Information

Official title A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Principal investigator Richard Tuli, MD
Description Gemcitabine will be administered by intravenous infusion of 1000 mg/m2 over 30 minutes on days 1, 8, 15 of the cycle. Intensity modulated radiation therapy (IMRT) will be given to a total dose of 36 Gy in 15 fractions (2.4 Gy per fraction, one fraction per day, 5 fractions per week, Monday through Friday) beginning on day 1. Veliparib will be administered per a dose escalation schema. The starting dose of veliparib is 20 mg BID based upon safety/efficacy data available. Dose escalation will continue in 20 mg increments until the maximum tolerated dose (MTD) is reached. Intra-patient dose escalation will not be allowed.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Cedars-Sinai Medical Center.